Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL87458 | 0.85 | TSHR (0.43) | ALDH1A1MEN1CYP1A2KMT2AESR1 | |
| SCHEMBL24041181 | 0.79 | LMNA (0.32) | NAALAD2ALDH1A1MEN1CYP1A2THRB | |
| SCHEMBL15130876 | 0.78 | HMGCR (0.42) | ALDH1A1TSHRHIF1AFFAR1CPT2 | |
| SCHEMBL17300290 | 0.78 | HMGCR (0.42) | ALDH1A1TSHRHIF1AFFAR1CPT2 | |
| SCHEMBL6681107 | 0.78 | NAALAD2 (0.41) | NAALAD2ALDH1A1MEN1CYP1A2THRB | |
| SCHEMBL26342933 | 0.78 | LMNA (0.38) | NAALAD2ALDH1A1MEN1CYP1A2THRB | |
| SCHEMBL764869 | 0.77 | — | — | |
| SCHEMBL12987414 | 0.77 | LMNA (0.47) | NAALAD2ALDH1A1MEN1CYP1A2THRB | |
| Hydrochloric Acid SCHEMBL15670496 | 0.75 | NAALAD2 (0.45) | NAALAD2ALDH1A1MEN1CYP1A2THRB | |
| SCHEMBL87591 | 0.74 | TSHR (0.32) | ALDH1A1TSHRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173076-A1 | METABOLICALLY STABLE PEPTIDE ANALOGS | UNIV STRASBOURG (FR) | 2023-06-08 | — | — | US | disclosed |
| US-11648305-B2 | Fluorocarbon-linked peptide formulation | Altimmune UK Ltd. (GB) | 2023-05-16 | — | — | US | disclosed |
| US-9962453-B2 | Immunogenic compound | ALTIMMUNE UK LIMITED (GB) | 2018-05-08 | — | — | US | disclosed |
| US-20170355734-A1 | Metabolically Stable Apelin Analogs in the Treatment of Disease Mediated by the Apelin Receptor | UNIVERSITE DE STRASBOURG (FR) | 2017-12-14 | — | — | US | disclosed |
| US-20170049898-A1 | INFLUENZA ANTIGEN DELIVERY VECTORS AND CONSTRUCTS | IMMUNE TARGETING SYSTEMS LIMITED (GB) | 2017-02-23 | — | — | US | disclosed |
| US-20160310603-A1 | IMMUNOGENIC COMPOUND | ALTIMMUNE UK LIMITED (GB) | 2016-10-27 | — | — | US | disclosed |
| US-9446143-B2 | Influenza antigen delivery vectors and constructs | ALTIMMUNE UK LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-20160199469-A1 | ONCOLOGY VACCINE | ALTIMMUNE UK LIMITED (GB) | 2016-07-14 | — | — | US | disclosed |
| US-20160106830-A1 | VACCINES AGAINST HEPATITIS B VIRUS | IMMUNE TARGETING SYSTEMS (ITS) LIMITED (GB) | 2016-04-21 | — | — | US | disclosed |
| US-9119811-B2 | Fluorocarbon-linked peptide formulation | VAXIN UK LIMITED (GB) | 2015-09-01 | — | — | US | disclosed |
| US-20150112042-A1 | Antigen Delivery Vectors and Constructs | ALTIMMUNE UK LIMITED (GB) | 2015-04-23 | — | — | US | disclosed |
| US-20140234356-A1 | INFLUENZA ANTIGEN DELIVERY VECTORS AND CONSTRUCTS | IMMUNE TARGETING SYSTEMS LTD. (GB) | 2014-08-21 | — | — | US | disclosed |
| US-8759281-B2 | Antigen delivery vectors and constructs | IMMUNE TARGETING SYSTEMS LTD. (GB) | 2014-06-24 | — | — | US | disclosed |
| US-20120315293-A1 | Antigen Delivery Vectors and Constructs | IMMUNE TARGETING SYSTEMS LTD. | 2012-12-13 | — | — | US | disclosed |
| US-8129333-B2 | Antigen delivery vectors and constructs | IMMUNE TARGETING SYSTEMS LTD. (GB) | 2012-03-06 | — | — | US | disclosed |
| US-20120034259-A1 | ANTIGEN DELIVERY VECTORS AND CONSTRUCTS | ALTIMMUNE UK LIMITED (GB) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150112042-A1 | Antigen Delivery Vectors and Constructs | LY96, CD74, CD69 | NAALAD2 1404/4885ALDH1A1 3392/4885MEN1 3700/4885 |
| US-20120315293-A1 | Antigen Delivery Vectors and Constructs | LY96, CD74, CD69 | NAALAD2 1404/4885ALDH1A1 3392/4885MEN1 3700/4885 |
| US-20140234356-A1 | INFLUENZA ANTIGEN DELIVERY VECTORS AND CONSTRUCTS | LY96, CD74, HAVCR2 | NAALAD2 771/4885ALDH1A1 2465/4885MEN1 4406/4885 |
| US-20170355734-A1 | Metabolically Stable Apelin Analogs in the Treatment of Disease Mediated by the Apelin Receptor | APLNR, AVPR2, AVPR1A | NAALAD2 191/4885ALDH1A1 1151/4885MEN1 429/4885 |
| US-20160199469-A1 | ONCOLOGY VACCINE | CD4, CD81, TP53 | NAALAD2 3522/4885ALDH1A1 4876/4885MEN1 85/4885 |
| US-20170049898-A1 | INFLUENZA ANTIGEN DELIVERY VECTORS AND CONSTRUCTS | LY96, CD74, HAVCR2 | NAALAD2 771/4885ALDH1A1 2465/4885MEN1 4406/4885 |
| US-20160106830-A1 | VACCINES AGAINST HEPATITIS B VIRUS | HLA-DRB1, CD4, HLA-B | NAALAD2 1649/4885ALDH1A1 4847/4885MEN1 2636/4885 |
| US-11648305-B2 | Fluorocarbon-linked peptide formulation | VIP, FGB, LNPEP | NAALAD2 371/4885ALDH1A1 4489/4885MEN1 319/4885 |
| US-20230173076-A1 | METABOLICALLY STABLE PEPTIDE ANALOGS | GPR119, GLP1R, GIPR | NAALAD2 1261/4885ALDH1A1 3147/4885MEN1 1092/4885 |
| US-20160310603-A1 | IMMUNOGENIC COMPOUND | CD74, HLA-DRB1, MICA | NAALAD2 697/4885ALDH1A1 4489/4885MEN1 3152/4885 |
| US-20120034259-A1 | ANTIGEN DELIVERY VECTORS AND CONSTRUCTS | LY96, CD74, CD69 | NAALAD2 1404/4885ALDH1A1 3392/4885MEN1 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.